Design Therapeutics Q2 Loss Narrows to $0.32/Share, Beating Estimates; Cash at $207M
DSGN has more than doubled off its 52-week low of $3.76.
Summary
Design Therapeutics posted a Q2 net loss of $20.17M ($0.32/share), beating the consensus estimate of $21.32M. Operating expenses were $22.18M, and the company ended the quarter with $207.4M in cash. The earnings release adds new clinical timeline details: 12-week RESTORE-FA data is now expected in Q1 2027, with a registrational plan update in Q4 2026. FECD trial data is delayed to 2027 due to a supply issue with DT-168 eye droppers. This follows today's earlier clinical update on RESTORE-FA trial modifications and DT-818 dosing initiation. The narrower loss and extended cash runway provide a modest positive signal, but the key value driver remains the upcoming Friedreich ataxia data readouts.
At the time of this announcement, DSGN was trading at $12.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $760.7M. The 52-week trading range was $3.76 to $17.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.